瑞康医药
(002589)
| 流通市值：45.61亿 | | | 总市值：50.26亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,707,482,764.51 | 7,295,858,461.63 | 5,406,533,649.77 | 3,543,520,195.09 |
| 营业收入 | 1,707,482,764.51 | 7,295,858,461.63 | 5,406,533,649.77 | 3,543,520,195.09 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 1,692,322,269.95 | 7,353,302,934.53 | 5,455,252,955.23 | 3,627,527,911.6 |
| 营业成本 | 1,489,245,910.43 | 6,519,801,097.22 | 4,782,191,171.16 | 3,166,861,738.37 |
| 利息支出 | - | 0 | - | - |
| 手续费及佣金支出 | - | 0 | - | - |
| 退保金 | - | 0 | - | - |
| 赔付支出净额 | - | 0 | - | - |
| 提取保险合同准备金净额 | - | 0 | - | - |
| 保单红利支出 | - | 0 | - | - |
| 分保费用 | - | 0 | - | - |
| 税金及附加 | 8,647,389.44 | 36,644,988.6 | 28,130,205.72 | 15,698,411.4 |
| 销售费用 | 55,225,875.51 | 328,917,549.86 | 259,673,913.69 | 181,812,208.2 |
| 管理费用 | 88,916,157.33 | 330,689,392.55 | 265,530,013.71 | 170,158,323.23 |
| 研发费用 | 2,711,920.75 | 20,910,773.07 | 16,505,849.42 | 11,198,402.43 |
| 财务费用 | 47,575,016.49 | 116,339,133.23 | 103,221,801.53 | 81,798,827.97 |
| 其中:利息费用 | 55,316,940.92 | 178,997,925.7 | 156,843,596.86 | 117,884,999.14 |
| 其中:利息收入 | 9,658,254.45 | 78,212,074.53 | 62,753,048.36 | 41,992,173.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | 4,902,905.63 | -890,896.12 | -890,896.12 |
| 加:投资收益 | 1,297,098.79 | 84,806,805.99 | 16,776,374.66 | 12,404,896.21 |
| 资产处置收益 | 88,849.32 | 1,817,272.56 | 988,939.25 | 173,176.52 |
| 资产减值损失(新) | 0 | - | 0 | - |
| 信用减值损失(新) | -158,423.18 | -26,501,315.05 | 47,531,933.39 | 53,240,838.15 |
| 其他收益 | 63,059.41 | 9,270,217.24 | 840,125.81 | 260,857.77 |
| 四、营业利润 | 16,451,078.9 | 16,851,413.47 | 16,527,171.53 | -18,818,843.98 |
| 加:营业外收入 | 308,730.45 | 4,195,902.18 | 4,572,867.91 | 4,491,752.35 |
| 减:营业外支出 | 443,151.16 | 18,360,066.96 | 16,555,021.57 | 1,058,168.26 |
| 五、利润总额 | 16,316,658.19 | 2,687,248.69 | 4,545,017.87 | -15,385,259.89 |
| 减:所得税费用 | 697,096.09 | -41,214,881.56 | -22,459,095.93 | -45,990,301.77 |
| 六、净利润 | 15,619,562.1 | 43,902,130.25 | 27,004,113.8 | 30,605,041.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 15,619,562.1 | 43,902,130.25 | 27,004,113.8 | 30,605,041.88 |
| 终止经营净利润 | 0 | - | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 10,372,213.68 | 16,071,175.45 | 12,136,626.07 | 18,166,445.28 |
| 少数股东损益 | 5,247,348.42 | 27,830,954.8 | 14,867,487.73 | 12,438,596.6 |
| 扣除非经常损益后的净利润 | 9,145,523.65 | -64,103,305.93 | 6,587,357.34 | 2,899,545.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.01 | 0.01 | 0.01 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0.01 | 0.01 |
| 九、综合收益总额 | 15,619,562.1 | 43,902,130.25 | 27,004,113.8 | 30,605,041.88 |
| 归属于母公司股东的综合收益总额 | 10,372,213.68 | 16,071,175.45 | 12,136,626.07 | 18,166,445.28 |
| 归属于少数股东的综合收益总额 | 5,247,348.42 | 27,830,954.8 | 14,867,487.73 | 12,438,596.6 |
| 公告日期 | 2026-04-25 | 2026-04-23 | 2025-10-30 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |